Skip to search formSkip to main contentSkip to account menu

T-1249

National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2019
2019
A Caulobacter crescentus Microbicide Protects from Vaginal Infection with HIV-1JR-CSF in Humanized Bone Marrow-Liver-Thymus Mice
Human immunodeficiency virus (HIV) disproportionally infects young women in sub-Saharan Africa. Current HIV-1 prevention options… 
2017
2017
Molecular dynamics simulations of T-2410 and T-2429 HIV fusion inhibitors interacting with model membranes: Insight into peptide behavior, structure and dynamics.
2013
2013
Conjugation of Cholesterol to HIV-1 Fusion Inhibitor C34 Increases Peptide-Membrane Interactions Potentiating Its Action
Recently, the covalent binding of a cholesterol moiety to a classical HIV-1 fusion inhibitor peptide, C34, was shown to… 
2008
2008
A Fusion Inhibitor Prevents Spread of Immunodeficiency Viruses, but Not Activation of Virus-Specific T Cells, by Dendritic Cells
ABSTRACT Dendritic cells (DCs) play a key role in innate immune responses, and their interactions with T cells are critical for… 
2007
2007
Evolution of genotypic and phenotypic resistance during chronic treatment with the fusion inhibitor T-1249.
T-1249 is a peptide HIV fusion inhibitor (FI) previously under development for use in FI-naive and experienced patients. Here we… 
Review
2006
Review
2006
Anti-HIV therapy: Current and future directions.
Although combinations of drugs that target the HIV reverse transcriptase and protease enzymes have clearly revolutionized the… 
2005
2005
Effect of naturally-occurring gp41 HR1 variations on susceptibility of HIV-1 to fusion inhibitors
Background:Sequence variations in the gp41 heptad repeat 1 (HR1) region have been identified in some treatment-naive HIV-1… 
Highly Cited
2004
Highly Cited
2004
HIV fusion inhibitor peptide T-1249 is able to insert or adsorb to lipidic bilayers. Putative correlation with improved efficiency.
T-1249 is a HIV fusion inhibitor peptide under clinical trials. Its interaction with biological membrane models (large… 
2004
2004
Resistance and replicative capacity of HIV-1 strains selected in vivo by long-term enfuvirtide treatment.
Enfuvirtide is the prototype member of a new class of anti HIV-1 agents, the fusion inhibitors (FI). In recent clinical trials… 
2003
2003
Gateways to clinical trials. March 2003.
Gateways to clinical Trials is a guide to the most recent clinical trials in current literature and congresses. The data in the… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)